Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)

NCT07799532 is registered in ClinicalTrials.gov with NervGen Pharma as lead sponsor.

NCT NCT07799532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07799532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)
Lead sponsor
NervGen Pharma
Phase
Phase 3
Overall status
Recruiting
Start date
September 28, 2026
Completion date
December 14, 2027
Enrollment
150 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spinal cord injury